

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human IFN- $\alpha$ / $\beta$ R1 in direct ELISA.
<b>Source</b>	Recombinant Monoclonal Rabbit IgG Clone # 2951C
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line, NS0-derived human IFN-alpha/beta R1 Gly26-Lys436 Accession # P17181
<b>Conjugate</b>	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
<b>Formulation</b>	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

<b>Flow Cytometry</b>	Titration recommended for optimal concentration with starting range of 0.1-1 $\mu$ g/1 million cells. Sample used for this experiment was U937 human histiocytic lymphoma cell line.
-----------------------	--

## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, 2 to 8 °C as supplied.</li> </ul>

## BACKGROUND

Interferon-alpha/beta receptor 1 (IFN- $\alpha$ / $\beta$  R1), also known as IFNAR1, is a 100-130 kDa member of the class II cytokine receptor family of proteins. These proteins form heterodimeric receptor complexes that mediate class II cytokine signals. Subunits of the different receptor complexes are shared and serve multiple functions (1). IFN- $\alpha$ / $\beta$  R1, in association with IFN- $\alpha$ / $\beta$  R2, is required for propagating anti-microbial signal transduction triggered by the type 1 interferons such as IFN- $\alpha$  and IFN- $\beta$  (2, 3). Mature human IFN- $\alpha$ / $\beta$  R1 consists of a 409 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 100 aa cytoplasmic domain (4). The ECD contains three tandem fibronectin type III repeats and is extensively glycosylated. Within the ECD, human IFN- $\alpha$ / $\beta$  R1 shares 47% and 50% aa identity with mouse and rat IFN- $\alpha$ / $\beta$  R1, respectively. Alternative splicing generates two additional isoforms that lack the transmembrane segment and either all or a portion of the cytoplasmic domain. IFN- $\alpha$ / $\beta$  R1 interacts very weakly or not at all with type 1 interferons and does not stably interact with IFN- $\alpha$ / $\beta$  R2. Ligands preferentially associate with IFN- $\alpha$ / $\beta$  R2, and this complex subsequently forms a stable ternary assembly with IFN- $\alpha$ / $\beta$  R1 (5-7). IFN- $\alpha$ / $\beta$  R1 also associates with IFN- $\gamma$  R2 even in the absence of IFN- $\gamma$  stimulation (3). IFN- $\alpha$ / $\beta$  R1 activation depends on tyrosine phosphorylation as well as palmitoylation of its cytoplasmic domain (8, 9). Rapid down-regulation of the receptor is accomplished by ligand-dependent or -independent pathways (e.g. VEGF R signaling, TLR signaling, or cellular stress) which induce its serine phosphorylation, ubiquitination, and degradation (10-13).

### References:

- Langer, J.A. *et al.* (2004) Cytokine Growth Factor Rev. **15**:33.
- Hwang, S.Y. *et al.* (1995) Proc. Natl. Acad. Sci. USA **92**:11284.
- Takaoka, A. *et al.* (2000) Science **288**:2357.
- Uze, G. *et al.* (1990) Cell **60**:225.
- Lamken, P. *et al.* (2004) J. Mol. Biol. **341**:303.
- Arduini, R.M. *et al.* (1999) Prot. Sci. **8**:1867.
- Kalie, E. *et al.* (2008) J. Biol. Chem. **283**:32925.
- Platanias, L.C. (2005) Nat. Rev. Immunol. **5**:375.
- Claudinon, J. *et al.* (2009) J. Biol. Chem. **284**:24328.
- Zheng, H. *et al.* (2011) Blood **118**:4003.
- Qian, J. *et al.* (2011) PLoS Pathogens **7**:e1002065.
- Bhattacharya, S. *et al.* (2010) J. Biol. Chem. **285**:2318.
- Bhattacharya, S. *et al.* (2011) J. Biol. Chem. **286**:22069.

**PRODUCT SPECIFIC NOTICES**

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.